Succinate and crystal form thereof as therapeutics
AssigneeAucentra Therapeutics Pty Ltd
InventorsShudong WANG, Hui WANG, Jinchen LV, Jun LIU
Life of this patent
Estimating the term…
Abstract
Disclosed are salts of N-Cyclopentyl-5-(2-((5-((4-ethylpiperazin-1-yl) methyl) pyridin-2-yl) amino)-5-fluoropyrim-idin-4-yl)-4-methylthiazol-2-amine and polymorphs thereof, which are inhibitors of protein kinases, in particular cyclin-dependent kinase 4/6 (CDK4/6), and can be used to treat proliferative disorders, such as cancer, and other diseases related to protein kinase/CDK activity.
Claims21
N-Cyclopentyl-5-(2-((5-((4-ethylpiperazin-1-yl) methyl) pyridin-2-yl) amino)-5-fluoropyrimidin-4-yl)-4-methylthiazol-2-amine succinate.
9-11. (canceled)
15-17. (canceled)
A method of inhibiting a cyclin-dependent kinase in a subject in need thereof, comprising administering to the subject N-Cyclopentyl-5-(2-((5-((4-ethylpiperazin-1-yl) methyl) pyridin-2-yl) amino)-5-fluoropyrimidin-4-yl)-4-methylthiazol-2-amine succinate.
(canceled)
Dependencies are inferred from the claim text.